PT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder

Derya Tilki, Robert S. Svatek, Pierre I. Karakiewicz, Giacomo Novara, Michael Seitz, Guru Sonpavde, Amit Gupta, Wassim Kassouf, Yves Fradet, Vincenzo Ficarra, Eila Skinner, Yair Lotan, Arthur I Sagalowsky, Christian G. Stief, Oliver Reich, Shahrokh F. Shariat

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: We assessed the prognostic value of pT3 bladder urothelial carcinoma substaging. Materials and Methods: We reviewed the records of 2,605 patients treated with radical cystectomy for bladder urothelial carcinoma at 6 international centers, of whom 808 (31.0%) had pT3 disease. No patient received systemic chemotherapy or radiotherapy preoperatively. Median followup was 45 months in survivors at last followup. Results: Median patient age was 68 years. Stage was pT3a in 310 patients (38.4%) and pT3b in 498 (61.6%). Of the patients 352 (43.6%) had metastasis to regional lymph nodes. Five-year recurrence-free (43.8% and 41.4%) and cancer specific (48.6% and 46.8%) survival estimates were similar in pT3a and pT3b cases (p = 0.277 and 0.625, respectively). Conversely in patients with pathologically negative lymph nodes pT3b substaging was associated with worse 5-year recurrence-free (60.7% vs 47.9%) and cancer specific (64.4% vs 55.0%) survival (p = 0.020 vs 0.048). Conclusions: Macroscopic perivesical fat extension (pT3b) is associated with a worse outcome than pT3a disease in lymph node negative cases of bladder urothelial carcinoma. Together with other features pT3 substaging may help identify patients with pT3 who could benefit from adjuvant chemotherapy.

Original languageEnglish (US)
Pages (from-to)470-474
Number of pages5
JournalJournal of Urology
Volume184
Issue number2
DOIs
StatePublished - 2010

Fingerprint

Urinary Bladder
Lymph Nodes
Carcinoma
Recurrence
Survival
Cystectomy
Adjuvant Chemotherapy
Survivors
Neoplasms
Radiotherapy
Fats
Neoplasm Metastasis
Drug Therapy

Keywords

  • carcinoma
  • mortality
  • neoplasm staging
  • urinary bladder
  • urothelium

ASJC Scopus subject areas

  • Urology

Cite this

Tilki, D., Svatek, R. S., Karakiewicz, P. I., Novara, G., Seitz, M., Sonpavde, G., ... Shariat, S. F. (2010). PT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. Journal of Urology, 184(2), 470-474. https://doi.org/10.1016/j.juro.2010.04.007

PT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. / Tilki, Derya; Svatek, Robert S.; Karakiewicz, Pierre I.; Novara, Giacomo; Seitz, Michael; Sonpavde, Guru; Gupta, Amit; Kassouf, Wassim; Fradet, Yves; Ficarra, Vincenzo; Skinner, Eila; Lotan, Yair; Sagalowsky, Arthur I; Stief, Christian G.; Reich, Oliver; Shariat, Shahrokh F.

In: Journal of Urology, Vol. 184, No. 2, 2010, p. 470-474.

Research output: Contribution to journalArticle

Tilki, D, Svatek, RS, Karakiewicz, PI, Novara, G, Seitz, M, Sonpavde, G, Gupta, A, Kassouf, W, Fradet, Y, Ficarra, V, Skinner, E, Lotan, Y, Sagalowsky, AI, Stief, CG, Reich, O & Shariat, SF 2010, 'PT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder', Journal of Urology, vol. 184, no. 2, pp. 470-474. https://doi.org/10.1016/j.juro.2010.04.007
Tilki, Derya ; Svatek, Robert S. ; Karakiewicz, Pierre I. ; Novara, Giacomo ; Seitz, Michael ; Sonpavde, Guru ; Gupta, Amit ; Kassouf, Wassim ; Fradet, Yves ; Ficarra, Vincenzo ; Skinner, Eila ; Lotan, Yair ; Sagalowsky, Arthur I ; Stief, Christian G. ; Reich, Oliver ; Shariat, Shahrokh F. / PT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. In: Journal of Urology. 2010 ; Vol. 184, No. 2. pp. 470-474.
@article{14486c655d6d40f2ae3ca6e15275365c,
title = "PT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder",
abstract = "Purpose: We assessed the prognostic value of pT3 bladder urothelial carcinoma substaging. Materials and Methods: We reviewed the records of 2,605 patients treated with radical cystectomy for bladder urothelial carcinoma at 6 international centers, of whom 808 (31.0{\%}) had pT3 disease. No patient received systemic chemotherapy or radiotherapy preoperatively. Median followup was 45 months in survivors at last followup. Results: Median patient age was 68 years. Stage was pT3a in 310 patients (38.4{\%}) and pT3b in 498 (61.6{\%}). Of the patients 352 (43.6{\%}) had metastasis to regional lymph nodes. Five-year recurrence-free (43.8{\%} and 41.4{\%}) and cancer specific (48.6{\%} and 46.8{\%}) survival estimates were similar in pT3a and pT3b cases (p = 0.277 and 0.625, respectively). Conversely in patients with pathologically negative lymph nodes pT3b substaging was associated with worse 5-year recurrence-free (60.7{\%} vs 47.9{\%}) and cancer specific (64.4{\%} vs 55.0{\%}) survival (p = 0.020 vs 0.048). Conclusions: Macroscopic perivesical fat extension (pT3b) is associated with a worse outcome than pT3a disease in lymph node negative cases of bladder urothelial carcinoma. Together with other features pT3 substaging may help identify patients with pT3 who could benefit from adjuvant chemotherapy.",
keywords = "carcinoma, mortality, neoplasm staging, urinary bladder, urothelium",
author = "Derya Tilki and Svatek, {Robert S.} and Karakiewicz, {Pierre I.} and Giacomo Novara and Michael Seitz and Guru Sonpavde and Amit Gupta and Wassim Kassouf and Yves Fradet and Vincenzo Ficarra and Eila Skinner and Yair Lotan and Sagalowsky, {Arthur I} and Stief, {Christian G.} and Oliver Reich and Shariat, {Shahrokh F.}",
year = "2010",
doi = "10.1016/j.juro.2010.04.007",
language = "English (US)",
volume = "184",
pages = "470--474",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - PT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder

AU - Tilki, Derya

AU - Svatek, Robert S.

AU - Karakiewicz, Pierre I.

AU - Novara, Giacomo

AU - Seitz, Michael

AU - Sonpavde, Guru

AU - Gupta, Amit

AU - Kassouf, Wassim

AU - Fradet, Yves

AU - Ficarra, Vincenzo

AU - Skinner, Eila

AU - Lotan, Yair

AU - Sagalowsky, Arthur I

AU - Stief, Christian G.

AU - Reich, Oliver

AU - Shariat, Shahrokh F.

PY - 2010

Y1 - 2010

N2 - Purpose: We assessed the prognostic value of pT3 bladder urothelial carcinoma substaging. Materials and Methods: We reviewed the records of 2,605 patients treated with radical cystectomy for bladder urothelial carcinoma at 6 international centers, of whom 808 (31.0%) had pT3 disease. No patient received systemic chemotherapy or radiotherapy preoperatively. Median followup was 45 months in survivors at last followup. Results: Median patient age was 68 years. Stage was pT3a in 310 patients (38.4%) and pT3b in 498 (61.6%). Of the patients 352 (43.6%) had metastasis to regional lymph nodes. Five-year recurrence-free (43.8% and 41.4%) and cancer specific (48.6% and 46.8%) survival estimates were similar in pT3a and pT3b cases (p = 0.277 and 0.625, respectively). Conversely in patients with pathologically negative lymph nodes pT3b substaging was associated with worse 5-year recurrence-free (60.7% vs 47.9%) and cancer specific (64.4% vs 55.0%) survival (p = 0.020 vs 0.048). Conclusions: Macroscopic perivesical fat extension (pT3b) is associated with a worse outcome than pT3a disease in lymph node negative cases of bladder urothelial carcinoma. Together with other features pT3 substaging may help identify patients with pT3 who could benefit from adjuvant chemotherapy.

AB - Purpose: We assessed the prognostic value of pT3 bladder urothelial carcinoma substaging. Materials and Methods: We reviewed the records of 2,605 patients treated with radical cystectomy for bladder urothelial carcinoma at 6 international centers, of whom 808 (31.0%) had pT3 disease. No patient received systemic chemotherapy or radiotherapy preoperatively. Median followup was 45 months in survivors at last followup. Results: Median patient age was 68 years. Stage was pT3a in 310 patients (38.4%) and pT3b in 498 (61.6%). Of the patients 352 (43.6%) had metastasis to regional lymph nodes. Five-year recurrence-free (43.8% and 41.4%) and cancer specific (48.6% and 46.8%) survival estimates were similar in pT3a and pT3b cases (p = 0.277 and 0.625, respectively). Conversely in patients with pathologically negative lymph nodes pT3b substaging was associated with worse 5-year recurrence-free (60.7% vs 47.9%) and cancer specific (64.4% vs 55.0%) survival (p = 0.020 vs 0.048). Conclusions: Macroscopic perivesical fat extension (pT3b) is associated with a worse outcome than pT3a disease in lymph node negative cases of bladder urothelial carcinoma. Together with other features pT3 substaging may help identify patients with pT3 who could benefit from adjuvant chemotherapy.

KW - carcinoma

KW - mortality

KW - neoplasm staging

KW - urinary bladder

KW - urothelium

UR - http://www.scopus.com/inward/record.url?scp=77955466728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955466728&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2010.04.007

DO - 10.1016/j.juro.2010.04.007

M3 - Article

C2 - 20620401

AN - SCOPUS:77955466728

VL - 184

SP - 470

EP - 474

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -